A large clinical trial has revealed that high-dose vitamin D supplementation does not reduce the severity of acute COVID-19 infections, but may offer a subtle benefit in preventing the development of long COVID symptoms, researchers at Mass General Brigham announced this week.
The study, published in The Journal of Nutrition, involved 1,747 adults who recently tested positive for COVID-19, along with 277 of their household contacts across the United States and Mongolia. Participants were randomly assigned to receive either a high dose of vitamin D3 (9,600 IU/day for two days, followed by 3,200 IU/day) or a placebo for four weeks. Researchers found no significant difference in symptom severity, hospital visits, or emergency care needs between the two groups.
“While we didn’t discover that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” said Dr. JoAnn Manson, senior author of the study and a physician at Mass General Brigham. The finding regarding long COVID emerged from an analysis of participants who consistently adhered to the vitamin D regimen, suggesting a potential reduction in the likelihood of experiencing lingering symptoms at eight weeks compared to those receiving the placebo.
The VIVID Trial, as the study is known, aimed to clarify the role of vitamin D in COVID-19, a topic that has generated considerable debate and numerous prior studies with mixed results. Vitamin D is known to be linked to immune health, but establishing a clear connection to COVID-19 outcomes has proven challenging. The trial did not find that vitamin D supplementation reduced the rate at which household contacts contracted COVID-19.
Approximately 17 million adults in the United States are currently experiencing long COVID, with roughly 8% of individuals reporting having faced the condition at some point, according to recent estimates. Long COVID symptoms can include fatigue, shortness of breath, and brain fog, significantly impacting quality of life. The potential for a relatively low-cost intervention like vitamin D supplementation to mitigate these long-term effects is driving further investigation.
Researchers emphasized that the observed signal for long COVID is preliminary and requires further validation through additional studies. The focus now shifts to understanding the mechanisms by which vitamin D might influence long COVID outcomes and identifying which individuals might benefit most from supplementation. Mass General Brigham has not announced a timeline for follow-up research.
Leave a Reply